首页> 外文期刊>Vaccine >Immunogenicity of varying dosages of 7-valent pneumococcal polysaccharide-protein conjugate vaccine in seniors previously vaccinated with 23-valent pneumococcal polysaccharide vaccine
【24h】

Immunogenicity of varying dosages of 7-valent pneumococcal polysaccharide-protein conjugate vaccine in seniors previously vaccinated with 23-valent pneumococcal polysaccharide vaccine

机译:预先接种23价肺炎球菌多糖疫苗的老年人中不同剂量7价肺炎球菌多糖蛋白复合疫苗的免疫原性

获取原文
获取原文并翻译 | 示例
           

摘要

In this dose-ranging study 220 seniors who had received the 23-valent pneumococcal polysaccharide (PnPS) vaccine at least 5 years prior to enrollment were assigned to receive one of four volumes (0.1, 0.5, 1 or 2 ml) of 7-valent pneumococcal conjugate (PnC) vaccine or a 0.5 ml dose of 23-valent PnPS vaccine. All participants received a reduced challenge dose of 0.1 ml of PnPS vaccine 1 year after enrollment. There was evidence of a dose response to PnC vaccine and antibody levels in the 1 ml PnC group tended to be significantly higher than in the PnPS group. A booster response to the challenge vaccination was not observed. Administration of a 1 ml dose of PnC vaccine is more immunogenic than 0.5 ml of PnPS vaccine in elderly adults previously vaccinated with PnPS vaccine.
机译:在这项剂量范围研究中,将220名在入组前至少5年接受过23价肺炎球菌多糖(PnPS)疫苗的老年人分配为接受4份(0.1、0.5、1或2 ml)7价疫苗之一肺炎球菌结合物(PnC)疫苗或0.5 ml剂量的23价PnPS疫苗。入选后1年,所有参与者均接受了0.1毫升PnPS疫苗的降低挑战剂量。有证据表明,对PnC疫苗的剂量反应和1 ml PnC组的抗体水平往往明显高于PnPS组。没有观察到对挑战疫苗的加强反应。在以前接种过PnPS疫苗的老年人中,与0.5 ml PnPS疫苗相比,接种1 ml剂量的PnC疫苗具有更高的免疫原性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号